Table 4. Prognostic factors for cancer-specific survival of patients with ESCC in each pTNM stage.

Variables	Patients	Category or characteristics	Univariate analyses			Multivariate analyses
			HR	95%CI	p value	HR	95%CI	p value
pTNM stage I	n = 73
Gender	11/62	(female / male)	1.450	0.181–11.610	0.7264
Age	23/46	(< 65 / ≥ 65)	1.358	0.340–5.434	0.6649
BMI	60/13	(≥ 18.5 / < 18.5)	2.224	0.460–10.760	0.3205
Alb	66/7	(≥ 3.5 / < 3.5)	5.148	1.061–24.965	0.0420	1.267	0.148–10.854	0.8290
CRP	67/6	(< 0.5 / ≥ 0.5)	7.636	1.477–39.482	0.0153	7.172	1.014–50.705	0.0483
GNRI	53/20	(≥ 97.1 / < 97.1)	5.537	1.477–20.759	0.0111	5.579	1.191–26.133	0.0291
Tumor size	54/139	(< 3 / ≥ 3)	0.920	0.247–3.428	0.9010
Differentiation	28/45	(well/other)	4.455	0.557–35.629	0.1590
SCC	60/13	(< 1.5 / ≥ 1.5)	2.436	0.504–11.764	0.2679
pTNM stage II	n = 41
Gender	5/36	(female / male)	0.723	0.160–3.275	0.6742
Age	18/23	(< 65 / ≥ 65)	1.131	0.378–3.383	0.8261
BMI	30/11	(≥ 18.5 / < 18.5)	1.399	0.427–4.577	0.5790
Alb	30/11	(≥ 3.5 / < 3.5)	2.376	0.767–7.360	0.1335
CRP	29/12	(< 0.5 / ≥ 0.5)	1.134	0.348–3.693	0.8344
GNRI	21/20	(≥ 97.1 / < 97.1)	5.599	1.525–20.566	0.0095
Tumor size	54/139	(< 3 / ≥ 3)	2.161	0.477–9.796	0.3179
Differentiation	15/26	(well / other)	2.662	0.731–9.691	0.1374
SCC	32/9	(< 1.5 / ≥ 1.5)	0.814	0.180–3.678	0.7889
pTNM stage III	n = 77
Gender	6/71	(female/male)	1.214	0.433–3.402	0.7122
Age	36/41	(< 65 / ≥ 65)	1.101	0.612–1.978	0.7483
BMI	54/23	(≥ 18.5 / < 18.5)	1.096	0.573–2.094	0.7823
Alb	63/14	(≥ 3.5 / < 3.5)	2.640	1.239–5.626	0.0119
CRP	52/25	(< 0.5 / ≥ 0.5)	1.242	0.665–2.321	0.4963
GNRI	36/41	(≥ 97.1 / < 97.1)	1.218	0.677–2.193	0.5109
Tumor size	54/139	(< 3 / ≥ 3)	1.431	0.512–4.000	0.4950
Differentiation	21/56	(well / other)	1.252	0.632–2.478	0.5191
SCC	47/30	(< 1.5 / ≥ 1.5)	0.806	0.441–1.473	0.4830